Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
Lucile Vanhersecke, Maxime Brunet, Jean‐Philippe Guégan, Christophe Rey, Antoine Bougoüin, Sophie Cousin, Sylvestre Le Moulec, Benjamin Besse, Yohann Loriot, Mathieu Larroquette, Isabelle Soubeyran, Maud Toulmonde, Guilhem Roubaud, Simon Pernot, Mathilde Cabart, François Chomy, Corentin Lefevre, Kévin Bourcier, Michèle Kind, Ilenia Giglioli, Catherine Sautès‐Fridman, Valérie Velasco, Félicie Courgeon, Ezoglin Oflazoglu, Ariel Savina, Aurélien Marabelle, Jean‐Charles Soria, Carine Bellera, Casimir Ledoux Sofeu, Alban Bessede, Wolf H. Fridman, François Le Loarer, Antoîne Italiano
Topics & Concepts
PD-L1ImmunotherapyImmune checkpointCD8Monoclonal antibodyBlockadeImmune systemAntibodyOncologyMedicineSurvival analysisImmunohistochemistryCancer researchInternal medicineImmunologyReceptorCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune Cell Function and Interaction